GAMMA Investing LLC Buys 110,776 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

GAMMA Investing LLC increased its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 14,129.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 111,560 shares of the company's stock after acquiring an additional 110,776 shares during the quarter. GAMMA Investing LLC owned approximately 0.07% of Option Care Health worth $3,899,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of OPCH. 111 Capital bought a new position in Option Care Health in the 4th quarter worth approximately $315,000. Mackenzie Financial Corp boosted its stake in shares of Option Care Health by 1.1% during the 4th quarter. Mackenzie Financial Corp now owns 49,579 shares of the company's stock worth $1,150,000 after acquiring an additional 556 shares in the last quarter. Peak Retirement Planning Inc. bought a new stake in shares of Option Care Health during the 4th quarter worth $1,026,000. Public Employees Retirement System of Ohio raised its position in Option Care Health by 21.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after buying an additional 332 shares during the period. Finally, PharVision Advisers LLC purchased a new position in Option Care Health during the 4th quarter valued at about $251,000. Institutional investors and hedge funds own 98.05% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on OPCH. JMP Securities reaffirmed a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research report on Tuesday, April 22nd. JPMorgan Chase & Co. upped their target price on Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and upped their target price for the stock from $38.00 to $40.00 in a research report on Wednesday, April 30th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Option Care Health currently has an average rating of "Moderate Buy" and a consensus price target of $35.50.

Option Care Health Stock Down 0.8%

Shares of NASDAQ OPCH traded down $0.27 during mid-day trading on Friday, reaching $31.60. 1,119,035 shares of the company's stock were exchanged, compared to its average volume of 1,870,572. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of 26.55, a PEG ratio of 2.30 and a beta of 0.74. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The business has a fifty day simple moving average of $32.22 and a 200 day simple moving average of $30.31. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The firm's revenue for the quarter was up 16.3% on a year-over-year basis. As a group, equities analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.